Aktie A1JBJ2 ASTRAZENECA PHARMA INDIA LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen AstraZeneca Pharma India Limited NSE India S.E.

Aktien

A1JBJ2

INE203A01020

ASTRAZEN

Markt geschlossen - NSE India S.E.
Andere Börsenplätze
 13:43:51 15.05.2024 		% 5 Tage % 1. Jan.
5.491 INR +0,62 % Intraday Chart für AstraZeneca Pharma India Limited +4,79 % -0,64 %
08.04. AstraZeneca Pharma India Limited genehmigt Ernennung von Bhavana Agrawal als Direktorin und Vollzeitdirektorin CI
25.03. AstraZeneca Pharma India Limited ernennt Vinay Sharma mit Wirkung zum 1. Juli 2024 zum Business Unit Head - Rare Disease CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director
AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India
Astrazeneca Pharma India Limited Announces Board Changes
AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
AstraZeneca Pharma India Limited Announces Board Changes
AstraZeneca Pharma India Limited Announces Directorate Appointments
AstraZeneca Gets Indian Drug Regulator's Nod to Import Andexanet Alfa Powder for Solution for Infusion
Astrazeneca Pharma to Launch Breast Cancer Treatment Drug in India in January 2024
India's Nifty set for muted open after steep drop
Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive)
AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
AstraZeneca Gets Indian Drug Regulator's Nod to Import Pharmaceutical Formulations for Palivizumab
Astrazeneca Pharma India Limited Receives Permission to Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Palivizumab
AstraZeneca Pharma India Limited Announces Management Changes
Astrazeneca Pharma India Limited Announces Retirement of Rajesh Marwaha as Whole-Time Director
AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head ­ Oncology with Effect from November 1, 2023
AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023
AstraZeneca Pharma India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A1JBJ2 Aktie
  4. A1JBJ2 Aktie
  5. Nachrichten AstraZeneca Pharma India Limited
  6. Andere Sprachen